List

For best search results, use the search terms first and then apply the filters
Reset

The Award database is continually updated throughout the year. As a result, data for FY19 is not expected to be complete until April, 2020.

  1. Long non coding RNA signatures to distinguish fibromyalgia syndrome from rheumatic diseases

    SBC: IQUITY LABS, INC.            Topic: NIAID

    No other group of diseases encompasses a greater pathophysiology than do the rheumatic diseases Spanning multiple organ systems clinical decisions often rely on coordinated efforts from primary care providers and rheumatologists to rule in or rule out differential diagnoses when treating inflammatory conditions such as rheumatoid arthritis RA and systemic lupus erythematosus SLE RA is a sym ...

    SBIR Phase I 2017 Department of Health and Human ServicesNational Institutes of Health
  2. A Preclinical Trial of Therapeutic Angiogenesis Plus Angioplasty and Stenting for Renal Vascular Disease

    SBC: Leflore Technologies LLC            Topic: 400

    Abstract Chronic kidney disease CKD is a progressive disorder affecting almost of the general population and this disease has shown a relentless growth over the past decades Patients with CKD have higher rates of hospitalization greater mortality shorter life expectancy and their healthcare costs are up to times more expensive than non CKD patients Thus treatments to slow halt ...

    STTR Phase I 2017 Department of Health and Human ServicesNational Institutes of Health
  3. Enabling point of care molecular diagnostics by developing an adaptive PCR instrument and on demand kit reagents

    SBC: BIOVENTURES, INC            Topic: 172

    Because of its high sensitivity polymerase chain reaction PCR is the gold standard for the diagnosis of many infectious diseases but generally only implemented in well equipped laboratories One of the major roadblocks for expanding PCR to point of care markets is the lack of simple robust single tube PCR designs which preserve its laboratory based high sensitivity and specificity In this F ...

    STTR Phase I 2017 Department of Health and Human ServicesNational Institutes of Health
  4. HLS Potent novel inhibitor of fibrinolytic hemorrhage

    SBC: Translational Sciences Inc.            Topic: NHLBI

    This SBIR Application is responsive to NHLBI Small Business Topics of Special Interest therapeutics that are of high programmatic interest HL Hemorrhage or bleeding is a serious or fatal complication of surgery Antifibrinolytic agents that inhibit plasmin mediated fibrinolysis can significantly reduce blood loss emergency reoperation morbidity and death in patients with severe hemor ...

    SBIR Phase I 2017 Department of Health and Human ServicesNational Institutes of Health
  5. Development of a Non adjuvanted VLP Vaccine against Stealth H N Influenza

    SBC: EPIVAX, INC.            Topic: NIAID

    DESCRIPTION provided by applicant The avian origin H N influenza virus that emerged in humans in China in presents a unique challenge to vaccine development because it is poorly immunogenic Neutralizing antibodies are not detected in acute phase infection Anti H antibody responses are significantly delayed and exhibit low avidity in comparison with antibodies generated following seas ...

    SBIR Phase I 2016 Department of Health and Human ServicesNational Institutes of Health
  6. Development of Tumor Proliferation PET Tracer FLT using a Low Cost Single Dose Automatic Production and Quality Control Biomarker Generator System

    SBC: ABT Molecular Imaging            Topic: 102

    DESCRIPTION provided by applicant Worldwide a person dies from cancer every seconds Positron emission tomography PET is an effective tool that is critical in diagnosing cancer and monitoring treatment efficacy PET imaging relies on use of short lived radioisotopes Commercial distribution of the most commonly used radio tracer F FDG has resulted in patient population coverage in ...

    SBIR Phase II 2016 Department of Health and Human ServicesNational Institutes of Health
  7. IGF OT IGF A STAGE BASED MOBILE INTERVENTION FOR SUBSTANCE USE DISORDERS IN PRIMARY CARE N DA POP SEPTEMBER FEBRUARY BASE AWARD

    SBC: Pro-Change Behavior Systems Inc            Topic: NIDA

    Not Available

    SBIR Phase I 2015 Department of Health and Human ServicesNational Institutes of Health
  8. IGF OT IGF VALIDATION OF MOBILE TECHNOLOGIES FOR CLINICAL ASSESSMENT

    SBC: Pro-Change Behavior Systems Inc            Topic: NCI

    Not Available

    SBIR Phase II 2015 Department of Health and Human ServicesNational Institutes of Health
  9. IGF OT IGF FY IWIN NAVIGATING YOUR PATH TO WELL BEING SBIR PHASE II BASE AWARD PERIOD OF PERFORMANCE

    SBC: Pro-Change Behavior Systems Inc            Topic: NIDA

    Not Available

    SBIR Phase II 2015 Department of Health and Human ServicesNational Institutes of Health
  10. Expressing humanized bacterial luciferase in stem cells: Moving beyond firefly luciferase to expand the informational capacity of animal models for regenerative medicine

    SBC: 490 BIOTECH INC            Topic: 200

    DESCRIPTION provided by applicant This Small Business Technology Transfer STTR Phase I project proposes to develop autonomously bioluminescent human stem cells for continuous reagent free and real time bioimaging to address the National Institutes of Healthandapos s request for new techniques for non invasive long term tracking of stem cell survivability engraftment and migration followi ...

    STTR Phase I 2015 Department of Health and Human ServicesNational Institutes of Health

Agency Micro-sites

SBA logo
Department of Agriculture logo
Department of Commerce logo
Department of Defense logo
Department of Education logo
Department of Energy logo
Department of Health and Human Services logo
Department of Homeland Security logo
Department of Transportation logo
Environmental Protection Agency logo
National Aeronautics and Space Administration logo
National Science Foundation logo
US Flag An Official Website of the United States Government